Gastrointestinal Bleeding in Hospitalized covid‐19 Patients: a propensity Score Matched Cohort Study

Accepted Article

---

This article is protected by copyright. All rights reserved

factors, length of stay, and others. In addition, the patients within our health system include diverse 

population from Long Island, Manhattan, Queens, Staten Island, NY. This makes the data more 

generalizable. Our study does have limitations.  The retrospective nature of the study has its inherit 

limitations.  Our data was unable to accurately differentiate between therapeutic dose anticoagulation 

or prophylactic dose anticoagulation. This was due to 

dose changes, kidney function, and switching 

between prophylactic and therapeutic doses for any given patient.  However, during the study period 

the majority of patients who were administered anticoagulation where were on prophylactic doses. 

Finally risk factors for patients admitted with a GI bleed were not analyzed as home medications and 

adherence could not be verified. 

In summary our data shows that anticoagulation therapy in COVID-19 patients may be tolerated from 

a gastrointestinal bleeding viewpoint.  Prospective studies are needed to confirm our findings. 

REFERENCES

1. Anon. Johns Hopkins University Coronavirus Resource Center. 2020.

2. Inamdar S, Benias PC, Liu Y, Sejpal D V., Satapathy SK, Trindade AJ. Prevalence, risk factors, 

and outcomes of hospitalized patients with COVID-19 presenting as acute pancreatitis. 

Gastroenterology 2020.

3. Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal Symptoms and COVID-19: Case-Control 

Study from the United States. Gastroenterology 2020.

4. Gadiparthi C, Perisetti A, Sayana H, Tharian B, Inamdar S, Korman A. Gastrointestinal Bleeding in 

Patients with Severe SARS-CoV-2. Am J Gastroenterol 2020; 115: 1283–5.

5. Cavaliere K, Levine C, Wander P, Sejpal D V., Trindade AJ. Management of upper GI bleeding in